Loading…
ADMA Biologics, Inc. is projected to rise to $10.59 by 2027, a +17% move from its current price of $9.08. ADMA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $8.91 | $9.09 | $9.27 | +0.06% |
| Jul 15 | $8.84 | $9.09 | $9.35 | +0.12% |
| Jul 16 | $8.79 | $9.10 | $9.42 | +0.18% |
| Jul 17 | $8.74 | $9.10 | $9.48 | +0.25% |
| Jul 18 | $8.71 | $9.11 | $9.53 | +0.31% |
| Jul 19 | $8.68 | $9.11 | $9.57 | +0.37% |
| Jul 20 | $8.65 | $9.12 | $9.62 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.65 | $9.12 | $9.62 | +0.43% |
| Week 2 | $8.50 | $9.16 | $9.87 | +0.86% |
| Week 3 | $8.39 | $9.20 | $10.08 | +1.30% |
| Week 4 | $8.31 | $9.24 | $10.27 | +1.73% |
| Week 5 | $8.24 | $9.28 | $10.45 | +2.17% |
| Week 6 | $8.18 | $9.32 | $10.61 | +2.61% |
| Week 7 | $8.13 | $9.36 | $10.77 | +3.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ADMA Biologics, Inc. is a healthcare company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company operates through the ADMA BioManufacturing and Plasma Collection Centers segments and offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency; ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics related to the prevention and treatment of S. pneumonia infection for an immunoglobulin.
In addition, the company operates source plasma collection facilities and sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Biologics, Inc. is a healthcare stock with a current price of $9.16 and a market capitalization of $2.12B. It is ranked 1976 by market size among its peers.
The forecasted path for ADMA suggests a rising average price target over time, beginning at $9.16 in 2026 and reaching higher levels in the decade ahead, with a max forecast of up to $76.04 by 2050. The long-term outlook includes rising ROIs, culminating in a 384.2% ROI by 2050 and a bullish sentiment in the later years.
A major floor 23.1% below — a decisive break under it would weaken the trend.
The nearest floor, 16.3% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 82.2% above — clearing it would confirm fresh momentum.
Key ADMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.18 | Sell | $9.10 | Sell |
| MA 10 | $8.89 | Buy | $8.96 | Buy |
| MA 20 | $8.70 | Buy | $8.78 | Buy |
| MA 50 | $8.65 | Buy | $9.15 | Sell |
| MA 100 | $10.76 | Sell | $10.64 | Sell |
| MA 200 | $13.81 | Sell | $12.75 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.76 | Neutral |
| Stoch RSI (14) | 69.03 | Neutral |
| CCI (20) | 93.66 | Neutral |
| Williams %R (14) | -21.11 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 4.49 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 78.89 | Neutral |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 0.75 | Buy |
| Ultimate (7,14,28) | 74.39 | Sell |
| Momentum (10) | 0.36 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 9.33 | Sell |
| ADX (14) | 17.25 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is labeled as BULLISH in sentiment.
The RSI(14) is 60, with the 50-day simple moving average at $8.79 and the 200-day simple moving average at $13.94. Support is listed at $7.60 and resistance at $9.16. The 30-day price range spans from $7.92 to $10.59, indicating the stock has traded within a roughly $2.67 window over the past month.
The current volatility and momentum align with a constructive near-term bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.60 | $9.08 | $12.17 | 0% | Neutral | |
| $8.64 | $10.59 | $13.60 | +17% | Neutral | |
| $8.36 | $10.46 | $13.82 | +15% | Neutral | |
| $9.02 | $11.47 | $15.49 | +26% | Bullish | |
| $9.04 | $11.65 | $16.04 | +28% | Bullish | |
| $9.09 | $11.88 | $16.63 | +31% | Bullish | |
| $10.40 | $13.76 | $19.54 | +52% | Bullish | |
| $11.58 | $15.48 | $22.29 | +71% | Bullish | |
| $12.37 | $16.72 | $24.38 | +84% | Bullish | |
| $12.52 | $17.10 | $25.22 | +88% | Bullish | |
| $16.75 | $23.94 | $37.08 | +164% | Bullish | |
| $26.55 | $40.93 | $68.18 | +351% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.60 | $9.08 | $10.70 | +0.00% |
| August 2026 | $7.88 | $9.23 | $11.06 | +1.65% |
| September 2026 | $8.15 | $9.60 | $11.60 | +4.03% |
| October 2026 | $8.20 | $9.70 | $11.80 | +1.02% |
| November 2026 | $8.15 | $9.68 | $11.84 | -0.26% |
| December 2026 | $8.30 | $9.89 | $12.17 | +2.26% |
Click any year to see its month-by-month ADMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADMA could reach as high as $12.17, with a base case around $9.08 and support toward $7.60 — roughly 0% from $9.08. Price action looks broadly range-bound.
Expect ADMA to range from $8.64 to $13.60 through 2027. The $10.59 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ADMA price prediction for 2028 points to an average of $10.46 (low $8.36, high $13.82) — a potential gain of +15% on today's $9.08. Price action looks broadly range-bound.
In 2029, ADMA is projected to trade between $9.02 and $15.49, averaging $11.47 — a potential gain of +26% from today's $9.08. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
ADMA Biologics, Inc.'s 2030 outlook centres on $11.65, within a $9.04 to $16.04 range. That is up +2% on the projected 2029 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2031, ADMA could reach as high as $16.63, with a base case around $11.88 and support toward $9.09 — roughly +31% from $9.08. Buyers look set to stay in control over this stretch.
Expect ADMA to range from $10.40 to $19.54 through 2032. The $13.76 average target implies a +52% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The ADMA price prediction for 2033 points to an average of $15.48 (low $11.58, high $22.29) — a potential gain of +71% on today's $9.08. Buyers look set to stay in control over this stretch.
In 2034, ADMA is projected to trade between $12.37 and $24.38, averaging $16.72 — a potential gain of +84% from today's $9.08. That is up +8% on the projected 2033 average. Momentum favours further upside here.
ADMA Biologics, Inc.'s 2035 outlook centres on $17.10, within a $12.52 to $25.22 range. That is up +2% on the projected 2034 average. That marks a +88% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ADMA could reach as high as $37.08, with a base case around $23.94 and support toward $16.75 — roughly +164% from $9.08. Momentum favours further upside here.
Expect ADMA to range from $26.55 to $68.18 through 2050. The $40.93 average target implies a +351% move from current prices. That is up +71% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADMA today (≈ 110.132159 ADMA) could be worth
$4,507.58
+$3,507.58 (+351%) by 2050 · US Dollar
Based on the average projected ADMA price of $40.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADMAwould be worth at today's price.
$1,000 invested in ADMA on Jul 10, 2025 (≈ 54.141854 ADMA) would be worth
$491.61
-$508.39 (-50.8%) today · 0.49× · US Dollar
Based on a ADMA entry price of $18.47 vs. today's $9.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.95 | $1,014.53 | +1.5% |
| 1 month ago | $8.48 | $1,070.75 | +7.1% |
| 3 months ago | $9.7 | $936.08 | -6.4% |
| 6 months ago | $17.93 | $506.41 | -49.4% |
| 1 year ago | $18.47 | $491.61 | -50.8% |
| All time (5.0y) ago | $1.45 | $6,262.07 | +526.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADMA forecast.
Our base-case forecast reaches $18.00 around 2040.
Implied market cap at $18.00: $4.17B
The multi-year forecast points to continued upside with gradual price progress and rising ROIs. In 2027 the average target is $10.72 with a 17.1% ROI, followed by 2028 at $10.68 (16.6% ROI), and 2029 at $11.86 (29.5% ROI). By 2030, the average target is $12.02 with a 31.3% ROI, and 2031 shows $12.36 (34.9% ROI).
The forecast envisions stronger gains in the early 2030s and beyond: 2032 average $14.58 (59.2% ROI), 2033 $16.29 (77.8% ROI), 2034 $17.59 (92% ROI), and 2035 $18.13 (98% ROI). By 2040 the average target rises to $25.71 with a 180.7% ROI, and by 2050 the average reaches $44.35 with a 384.2% ROI. The sentiment shifts to BULLISH in the later years, reflecting an expectation of meaningful appreciation relative to today.
These are estimates, not guarantees, and actual results may vary given market dynamics and company-specific factors. The figures reflect the stated year-by-year targets and should be considered in the context of broader market risks and volatility.
Tap a question to reveal the answer.
Avg $12.02; min $9.21; max $16.80; ROI 31.3%; sentiment BULLISH.
The forecast shows growth over time with higher average targets and ROIs by 2030–2050, though 2026 is neutral and annualized volatility is 40%. Not a guarantee, but longer-term targets imply meaningful upside to 2050 (avg $44.35, ROI 384.2%).
The 2050 max forecast is $76.04, with a 2050 average of $44.35. Reaching $50 would be possible within the forecast horizon if the high targets are realized by 2050.
Low $7.92; High $10.59.
Current price $9.16; Market cap $2.12B.
ADMA Biologics, Inc. Community Discussion
0Share your ADMA Biologics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.